Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amidst Bullish Momentum

Open Interest and Volume Dynamics

On 23 Apr 2026, Glenmark Pharmaceuticals recorded an open interest (OI) of 45,460 contracts in its derivatives, marking a substantial increase of 9,225 contracts or 25.46% compared to the previous OI of 36,235. This sharp rise in OI is accompanied by a robust volume of 78,258 contracts traded, indicating active participation from both institutional and retail investors.

The futures segment alone accounted for a value of approximately ₹1,73,390.93 lakhs, while the options segment’s notional value stood at an impressive ₹5,14,437.56 lakhs. The combined derivatives turnover reached ₹1,80,825.34 lakhs, underscoring the stock’s liquidity and attractiveness for large trades.

Price Performance and Market Positioning

Glenmark’s underlying stock price hit a new 52-week and all-time high of ₹2,359.40 during intraday trading, reflecting a 5.33% gain on the day. The stock outperformed its Pharmaceuticals & Biotechnology sector by 1.24%, while the broader Sensex declined by 0.76%, highlighting Glenmark’s relative strength in a challenging market environment.

Over the past three consecutive trading sessions, Glenmark has delivered a cumulative return of 3.29%, signalling sustained bullish momentum. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which further confirms the positive technical setup and investor optimism.

Interestingly, despite the price rally, delivery volumes have fallen by 29.22% to 1.58 lakh shares on 22 Apr compared to the five-day average, suggesting that short-term traders and derivatives players may be driving the recent surge rather than long-term holders.

Mojo Score Upgrade and Market Capitalisation

MarketsMOJO recently upgraded Glenmark Pharmaceuticals’ Mojo Grade from Buy to Strong Buy on 8 Apr 2026, reflecting improved fundamentals and technical outlook. The company now holds a robust Mojo Score of 81.0, signalling strong buy-side interest and favourable risk-reward dynamics.

With a market capitalisation of ₹64,659 crore, Glenmark is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector. This positioning offers a blend of growth potential and relative stability, attracting investors seeking exposure to the healthcare space amid ongoing global health challenges and innovation in drug development.

Interpreting the Open Interest Surge

The 25.46% increase in open interest suggests that new positions are being initiated rather than existing ones being squared off. This typically indicates fresh directional bets, with market participants positioning for further upside in Glenmark’s shares. The concurrent rise in volume supports this interpretation, as higher volumes alongside rising OI often point to strong conviction among traders.

Given the stock’s recent breakout to all-time highs and its outperformance relative to sector peers, it is plausible that bullish sentiment is driving the derivatives activity. Traders may be employing futures and call options to leverage anticipated gains, while put option activity remains subdued, reflecting limited hedging or bearish bets.

Moreover, the weighted average price data reveals that more volume was traded closer to the day’s low price, which could indicate accumulation by buyers at relatively attractive levels during intraday dips. This behaviour often precedes sustained upward trends as demand absorbs selling pressure.

Liquidity and Trading Considerations

Liquidity remains ample for Glenmark, with the stock’s traded value supporting trade sizes up to ₹1.67 crore based on 2% of the five-day average traded value. This ensures that institutional investors can enter or exit positions without significant market impact, further encouraging participation in derivatives markets.

However, the noted decline in delivery volumes suggests that while derivatives activity is heating up, actual shareholding changes are more muted. This divergence may reflect speculative positioning or short-term trading strategies rather than fundamental accumulation by long-term investors.

Outlook and Investor Implications

Glenmark Pharmaceuticals’ recent surge in open interest and volume, combined with its strong price performance and upgraded Mojo Grade, paints a bullish picture for the stock in the near term. The pharmaceutical sector continues to benefit from robust demand for innovative therapies and a favourable regulatory environment, which supports earnings growth prospects.

Investors should note that the derivatives market activity signals increased speculative interest, which can lead to heightened volatility. While the technical indicators and fundamentals align positively, prudent risk management remains essential, especially given the mid-cap nature of the stock.

For long-term investors, the strong fundamentals and consistent execution underpin Glenmark’s potential as a growth stock within the healthcare space. Meanwhile, traders may find opportunities in the derivatives segment to capitalise on momentum, provided they monitor open interest trends and volume patterns closely.

Overall, Glenmark Pharmaceuticals stands out as a compelling candidate for portfolios seeking exposure to the Pharmaceuticals & Biotechnology sector, supported by a strong market positioning and active derivatives interest that could drive further price discovery.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today